Indication
NRG1 Fusion
3 clinical trials
3 products
Clinical trial
Treatment Plan of the HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorStatus:
Product
MCLA-128Clinical trial
A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)Status: Recruiting, Estimated PCD: 2026-12-31
Product
ZenocutuzumabClinical trial
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene FusionsStatus: Terminated, Estimated PCD: 2021-04-09
Product
Tarloxotinib